SGLT2 Inhibitor

4 Drugs classified under this drug class

SGLT2 Inhibitor. Dapagliflozin (propanediol monohydrate) 5 mg, 10 mg.
F.C. TAB.: 7, 14, 28, 30, 90, 98.
Monother., add-on comb. ther.: 10
mg×1/d for monother., add-on comb.
ther. with other glucose-low. med. prod.
include. insulin. Pts. with severe hep.
imair. init. recom. dose is 5 mg If well
tolerated, the dose may be incr. to 10
mg.
Indic. In adults aged 18 yrs., older with
type 2 diabetes mell. to improve
glycaemic control as: Monother.: when
diet and exercise alone do not provide
adequate glycaemic control in pts. for
whom use of metformin is considered
inappropriate due to intolerance. Add-on
comb. ther.: In comb. with other glucoselow.
med. products includ. insulin, when these,
together with diet and exercise, do not
provide adequate glycaemic control.
C/I: Hypersens.

DPP-4 Inhibitor, SGLT2 Inhibitor. Empagliflozin 10, 25 mg, Linagliptin 5 mg.
F.C.TABS.: 30. The recomm. dose of this drug is 10 mg empagliflozin/5 mg linagliptin once dly. in the morn., taken with/ without food. In pts. tolerat. this formul., the dose may be incr. to 25 mg empagliflozin/5 mg linagliptin once dly. See lit.
Indic. as an adjunct to diet and exercise to improve glycem. control in adults with type 2 diab. mell. when tmt. with both empagliflozin and linagliptin is approp..
C/I: Sev. ren. impair., end-stage renal dis., or dialysis. Hist. of hypersens. reaction to linagliptin, such as anaphylax., angioedema, exfoliative skin condit., urticaria, or bronch. hyperreactivity. Hist. of serious hypersens. reaction to empagliflozin.

SGLT2 Inhibitor. Empagliflozin 10 mg, 25 mg.
F.C. TABS.: 30×10, 25 mg. Monother. and add-on comb.: recom. start. dose is 10mg×1/d for monother. and add-on comb. ther. with other glucose-low. med. products includ. insulin. In pts. tolerat. empagliflozin 10 mg×1/d, the dose can be incr. to 25 mg×1/d. Max. dly. dose is 25 mg. When used in comb. with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may be consid. to reduce the risk of hypoglycaemia. In pts. with volume depletion, correcting this condition prior to init. of Empagliflozin is recomm. See lit.
Indic. as an adjunct to diet and exercise to improve glyc. control in adults with type 2 diabetes mell. Limitation of use: not recom. for pts. with type 1 diabetes or for the tmt. of diabetic ketoacidosis.
C/I: Hypersens. Severe renal impair., endstage renal dis. /dialysis.

Biguanide, SGLT2 Inhibitor. Empagliflozin 5 mg, 12.5 mg, Metformin Hydrochloride 500, 850, 1000 mg.
F.C. TABS.: 14, 60, 180. In pts. with volume depletion not prev. treated with empagliflozin, correct this condit. before init. Adjust dosing based on effectiveness and tolerab. while not exceed. the max. recom. dly. dose of metformin HCl 2000 mg and empagliflozin 25 mg.
Twice dly. with meals; with gradual dose escalat. to reduce the GI side effect. due to metformin. See lit.
Indic. in adult. aged 18 yrs. and older with type 2 diab. mell. as an adjunct to diet and exercise to improve glycaemic control in pts. inadequat. control. on their maxim. tolerat. dose of metformin alone. In pts. inadequat. control. with metformin in comb. with other glucose-low. med. products, includ. insulin. In pts. already being treated with the comb. of empagliflozin and metformin as separate tabs.
C/I: Pts. with Moder.- sev. renal impair. (eGFR less than 45 mL/min/1.73 m2), end stage renal dis., or dial. Acute /chron. metabol. acidosis, includ. diabet. ketoacidosis. Diabet. ketoacidosis should be treated with insulin. His. of serious hypersens. react. to empagliflozin or metformin.